SCHEMBL4359807

SCHEMBL4359807

O=[N+]([O-])c1cncc(Cl)c1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 5/20 0.52
ALDH1A1 P00352 3/20 0.46
HTT P42858 3/20 0.46
LMNA P02545 2/20 0.46
MAPK1 P28482 2/20 0.46
CYP3A4 P08684 1/20 0.42
USP7 Q93009 1/20 0.41
USP47 Q96K76 1/20 0.41
TDP1 Q9NUW8 3/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 2/20 0.41
MAPT P10636 2/20 0.41
PKM P14618 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HSP90AA1 P07900 1/20 0.41
OPRK1 P41145 1/20 0.41
TSHR P16473 1/20 0.38
VCAM1 P19320 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5656200 0.85 GPR35 (0.56) GPR35ALDH1A1HTTLMNAMAPK1
SCHEMBL4351783 0.79 ALDH1A1 (0.49) GPR35ALDH1A1HTTLMNAMAPK1
SCHEMBL12341859 0.76 ALDH1A1 (0.49) GPR35ALDH1A1HTTLMNAMAPK1
SCHEMBL31487506 0.76 ALDH1A1 (0.46) GPR35ALDH1A1HTTLMNAMAPK1
SCHEMBL30774912 0.76 GPR35 (0.42) GPR35ALDH1A1MAPK1CYP3A4TDP1
SCHEMBL690072 0.76 GPR35 (0.42) GPR35ALDH1A1MAPK1CYP3A4TDP1
SCHEMBL8159027 0.76 GPR35 (0.52) GPR35ALDH1A1MAPK1TDP1KDM4E
SCHEMBL16787435 0.76 ALDH1A1 (0.46) ALDH1A1HTTLMNAMAPK1CYP3A4
SCHEMBL15770940 0.76 ALDH1A1 (0.46) GPR35ALDH1A1HTTLMNAMAPK1
SCHEMBL29951602 0.73 ERN1 (0.56) ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136577-A1 HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS C4X DISCOVERY LIMITED (GB) 2025-05-01 US disclosed
WO-2025058977-A1 MODULATORS OF CORONAVIRUS 3C-LIKE PROTEASE AND USES THEREOF Vir Biotechnology, Inc. (US) 2025-03-20 WO disclosed
EP-4472734-A1 HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS C4X Discovery Limited (GB) 2024-12-11 EP disclosed
CN-119095837-A Heterocyclic derivatives as MALT1 inhibitors 希四克斯探索有限公司 2024-12-06 CN disclosed
WO-2023148501-A1 HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS C4X DISCOVERY LIMITED (GB) 2023-08-10 WO disclosed
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-11-13 US disclosed
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2018-06-07 US disclosed
US-9873687-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-01-23 US disclosed
CN-105377837-B N (heteroaryl) sulfamide derivative as S100 inhibitor 活跃生物技术有限公司 2017-08-04 CN disclosed
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-04-28 US disclosed
CN-105377837-A N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB 2016-03-02 CN disclosed
EP-2925743-B1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-02-03 EP disclosed
EP-2925743-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS Active Biotech AB (SE) 2015-10-07 EP disclosed
US-20150175608-A1 NOVEL 4-SUBSTITUTED 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH BENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS JANSSEN INFECTIOUS DISEASES BVBA (BE) 2015-06-25 US disclosed
US-20150175608-A1 NOVEL 4-SUBSTITUTED 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH BENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS JANSSEN INFECTIOUS DISEASES BVBA (BE) 2015-06-25 US disclosed
US-20150158862-A1 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS JANSSEN R&D IRELAND (US) 2015-06-11 US disclosed
US-20150158862-A1 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS JANSSEN R&D IRELAND (US) 2015-06-11 US disclosed
WO-2014184234-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2014-11-20 WO disclosed
WO-2009108551-A2 HETEROARYL AMIDE ANALOGUES H. LUNDBECK A/S (DK) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158862-A1 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS ZC3HAV1, HELZ, SARS1 GPR35 2857/4885ALDH1A1 3047/4885HTT 1042/4885
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors S100A9, S100B, S100A10 GPR35 524/4885ALDH1A1 4109/4885HTT 1197/4885
US-20250136577-A1 HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS MALT1, SQSTM1, FKBP1A GPR35 3756/4885ALDH1A1 1855/4885HTT 783/4885
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100B, S100A10 GPR35 524/4885ALDH1A1 4109/4885HTT 1197/4885
US-20150175608-A1 NOVEL 4-SUBSTITUTED 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH BENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS SARS1, HRH4, H1-4 GPR35 3151/4885ALDH1A1 2742/4885HTT 1655/4885
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100A4, S100B GPR35 1417/4885ALDH1A1 4370/4885HTT 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.